Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000217197 | SCV000273224 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-08-29 | criteria provided, single submitter | clinical testing | The p.H1126P variant (also known as c.3377A>C), located in coding exon 13 of the PALB2 gene, results from an A to C substitution at nucleotide position 3377. The histidine at codon 1126 is replaced by proline, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000469669 | SCV000550617 | uncertain significance | Familial cancer of breast | 2022-08-04 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with PALB2-related conditions. This variant is present in population databases (rs752373316, gnomAD 0.009%). This sequence change replaces histidine, which is basic and polar, with proline, which is neutral and non-polar, at codon 1126 of the PALB2 protein (p.His1126Pro). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 229867). |
Color Diagnostics, |
RCV000217197 | SCV001354179 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-12-05 | criteria provided, single submitter | clinical testing | This missense variant replaces histidine with proline at codon 1126 of the PALB2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with PALB2-related disorders in the literature. This variant has been identified in 3/251428 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV000469669 | SCV005053943 | uncertain significance | Familial cancer of breast | 2023-12-12 | criteria provided, single submitter | clinical testing |